Citadel Advisors
GMAB icon

Citadel Advisors’s Genmab GMAB Stock Holding History

Citadel Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19,102
Closed -$572K – 13443
2025
Q4 		$588K Sell
19,102
-32,371
-63% -$1.01M ﹤0.01% 8633
2025
Q3 		$1.58M Sell
51,473
-3,517,711
-99% -$85.7M ﹤0.01% 6555
2025
Q2 		$73.7M Sell
3,569,184
-857,470
-19% -$17.6M 0.01% 953
2025
Q1 		$86.7M Buy
4,426,654
+1,334,510
+43% +$28M 0.02% 777
2024
Q4 		$64.5M Buy
3,092,144
+1,792,288
+138% +$39.4M 0.01% 1058
2024
Q3 		$31.7M Buy
1,299,856
+28,968
+2% +$774K 0.01% 1626
2024
Q2 		$31.9M Buy
1,270,888
+1,222,750
+2,540% +$34.7M 0.01% 1553
2024
Q1 		$1.44M Sell
48,138
-107,383
-69% -$3.15M ﹤0.01% 6168
2023
Q4 		$4.95M Sell
155,521
-89,390
-36% -$2.81M ﹤0.01% 3809
2023
Q3 		$8.64M Sell
244,911
-28,223
-10% -$1.08M ﹤0.01% 2872
2023
Q2 		$10.4M Sell
273,134
-158,719
-37% -$6.33M ﹤0.01% 2631
2023
Q1 		$16.3M Buy
431,853
+30,699
+8% +$1.18M ﹤0.01% 2165
2022
Q4 		$17M Buy
401,154
+85,560
+27% +$3.53M ﹤0.01% 2136
2022
Q3 		$10.1M Buy
315,594
+76,206
+32% +$2.68M ﹤0.01% 2735
2022
Q2 		$7.78M Buy
239,388
+115,930
+94% +$3.76M ﹤0.01% 3018
2022
Q1 		$4.47M Buy
+123,458
New +$4.24M ﹤0.01% 4401
2021
Q4 		– Sell
-21,039
Closed -$877K – 14167
2021
Q3 		$919K Buy
21,039
+748
+4% +$33.6K ﹤0.01% 8368
2021
Q2 		$828K Buy
+20,291
New +$783K ﹤0.01% 8850
2021
Q1 		– Sell
-239,132
Closed -$8.99M – 13370
2020
Q4 		$9.72M Sell
239,132
-43,578
-15% -$1.63M ﹤0.01% 2668
2020
Q3 		$10.3M Buy
282,710
+30,339
+12% +$1.1M ﹤0.01% 2257
2020
Q2 		$8.55M Buy
252,371
+227,512
+915% +$6.2M ﹤0.01% 2410
2020
Q1 		$527K Sell
24,859
-417,900
-94% -$9.32M ﹤0.01% 6381
2019
Q4 		$9.89M Sell
442,759
-714,061
-62% -$15.6M ﹤0.01% 2207
2019
Q3 		$23.4M Buy
+1,156,820
New +$22.8M 0.01% 1328

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Citadel Advisors's GMAB Position: Q1 2026 in Review

Citadel Advisors sold out of Genmab (GMAB) in Q1 2026, closing a stake of 19,102 shares — an estimated $572K sold.

Citadel Advisors first reported a position in GMAB in Q3 2019 and held it in 24 quarters. The position peaked at $86.7M in Q1 2025. 272 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

  • Citadel Advisors reported no remaining Genmab position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 19,102 Genmab shares in Q1 2026, an estimated $572K.
  • Citadel Advisors first reported a position in Genmab in Q3 2019 and held it in 24 quarters.
  • Citadel Advisors's Genmab position peaked at $86.7M in Q1 2025.
  • 272 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.